CA1079720A - Methode pour la preparation d'une poudre cristalline de cephalotine sodique se dissolvant rapidement pour administration par voie parenterale - Google Patents

Methode pour la preparation d'une poudre cristalline de cephalotine sodique se dissolvant rapidement pour administration par voie parenterale

Info

Publication number: CA1079720A
Authority: CA; Canada
Prior art keywords: percent; cephalothin sodium; solution; sodium; process according
Prior art date: 1977-11-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA291,717A

Other languages

English (en)

Inventor

Michael D. Cise

Michael L. Roy

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eli Lilly and Co

Original Assignee

Eli Lilly and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-11-24

Filing date

1977-11-24

Publication date

1980-06-17

1977-11-24 Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co

1977-11-24 Priority to CA291,717A priority Critical patent/CA1079720A/fr

1980-06-17 Application granted granted Critical

1980-06-17 Publication of CA1079720A publication Critical patent/CA1079720A/fr

Status Expired legal-status Critical Current

Links

229960000603 cefalotin Drugs 0.000 title claims abstract description 92
XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 title claims abstract description 91
238000000034 method Methods 0.000 title claims abstract description 44
238000007911 parenteral administration Methods 0.000 title claims abstract description 8
239000000843 powder Substances 0.000 title abstract description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 60
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 42
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
239000002904 solvent Substances 0.000 claims abstract description 27
238000004108 freeze drying Methods 0.000 claims abstract description 22
238000002360 preparation method Methods 0.000 claims description 16
239000013078 crystal Substances 0.000 claims description 14
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 11
229910052753 mercury Inorganic materials 0.000 claims description 11
239000003708 ampul Substances 0.000 claims description 10
238000001816 cooling Methods 0.000 claims description 9
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
230000008018 melting Effects 0.000 claims description 6
238000002844 melting Methods 0.000 claims description 6
229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
238000010792 warming Methods 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 2
239000008024 pharmaceutical diluent Substances 0.000 abstract description 3
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 abstract description 2
239000000243 solution Substances 0.000 description 55
235000019441 ethanol Nutrition 0.000 description 29
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
238000000859 sublimation Methods 0.000 description 9
230000008022 sublimation Effects 0.000 description 9
229960004756 ethanol Drugs 0.000 description 7
239000008215 water for injection Substances 0.000 description 7
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
238000001914 filtration Methods 0.000 description 6
238000002425 crystallisation Methods 0.000 description 5
230000008025 crystallization Effects 0.000 description 5
238000011049 filling Methods 0.000 description 5
238000005092 sublimation method Methods 0.000 description 5
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
238000010899 nucleation Methods 0.000 description 4
230000006911 nucleation Effects 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 3
230000008023 solidification Effects 0.000 description 3
238000007711 solidification Methods 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000010981 drying operation Methods 0.000 description 2
GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
XTUSEBKMEQERQV-UHFFFAOYSA-N propan-2-ol;hydrate Chemical compound O.CC(C)O XTUSEBKMEQERQV-UHFFFAOYSA-N 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
238000003860 storage Methods 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
238000003915 air pollution Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000012296 anti-solvent Substances 0.000 description 1
239000010425 asbestos Substances 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
235000021539 instant coffee Nutrition 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229910052895 riebeckite Inorganic materials 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000004383 yellowing Methods 0.000 description 1

Landscapes

Cephalosporin Compounds (AREA)

CA291,717A 1977-11-24 1977-11-24 Methode pour la preparation d'une poudre cristalline de cephalotine sodique se dissolvant rapidement pour administration par voie parenterale Expired CA1079720A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA291,717A CA1079720A (fr)	1977-11-24	1977-11-24	Methode pour la preparation d'une poudre cristalline de cephalotine sodique se dissolvant rapidement pour administration par voie parenterale

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA291,717A CA1079720A (fr)	1977-11-24	1977-11-24	Methode pour la preparation d'une poudre cristalline de cephalotine sodique se dissolvant rapidement pour administration par voie parenterale

Publications (1)

Publication Number	Publication Date
CA1079720A true CA1079720A (fr)	1980-06-17

Family

ID=4110130

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA291,717A Expired CA1079720A (fr)	1977-11-24	1977-11-24	Methode pour la preparation d'une poudre cristalline de cephalotine sodique se dissolvant rapidement pour administration par voie parenterale

Country Status (1)

Country	Link
CA (1)	CA1079720A (fr)

1977
- 1977-11-24 CA CA291,717A patent/CA1079720A/fr not_active Expired

Similar Documents

Publication	Publication Date	Title
US4029655A (en)	1977-06-14	Method of preparing stable sterile crystalline cephalosporins for parenteral administration
US4146971A (en)	1979-04-03	Method of preparing a rapidly dissolving powder of sterile crystalline cefazolin sodium for parenteral administration
JP2011021042A (ja)	2011-02-03	ホスホリパーゼ阻害剤の［［３−（２−アミノ−１，２−ジオキソエチル）−２−エチル−１−フェニルメチル）−１ｈ−インドール−４−イル］オキシ］酢酸ナトリウムを含む薬学的組成物
US5424069A (en)	1995-06-13	Production of crystalline penem
CA1079720A (fr)	1980-06-17	Methode pour la preparation d'une poudre cristalline de cephalotine sodique se dissolvant rapidement pour administration par voie parenterale
US4132848A (en)	1979-01-02	Method of preparing a rapidly dissolving powder of crystalline cephalothin sodium for parenteral administration
NO873513L (no)	1988-02-22	Nye applikasjonsformer for alfa-interferoner.
GB1589317A (en)	1981-05-13	Freeze drying cephalothin sodium
US4002748A (en)	1977-01-11	Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration
RU1836079C (ru)	1993-08-23	Способ получени лиофилизата
JPS6019759B2 (ja)	1985-05-17	非経口投予用１１１１５１５２１３９１９９東京都中央区京橋２丁目３番１３号
IE45995B1 (en)	1983-01-26	Improvements in or relating to freeze drying cephalothin sodium
FI68055B (fi)	1985-03-29	Foerfarande foer framstaellning av ett snabbloesligt pulver avristallint cefalotinnatrium
SE416733B (sv)	1981-02-02	Forfarande for framstellning av i huvudsak kristallint cefalotinnatrium
DK142420B (da)	1980-10-27	Fremgangsmåde til fremstilling af i det væsentlige krystallinsk natriumcephalotin.
US4070456A (en)	1978-01-24	Compositions containing dioctyl calcium sulfosuccinate
DK143942B (da)	1981-11-02	Fr&mgangsmaade til fremstilling af i det vaesentlige krystallinsk natrium-cefazolin
SE416734B (sv)	1981-02-02	Forfarande for framstellning av i huvudsak kristallint, snabblosligt cefazolinnatrium
FI67855B (fi)	1985-02-28	Foerfarande foer framstaellning av ett vaesentligen kristallint laettloesligt cefazolinnatrium
JPS6168412A (ja)	1986-04-08	医薬品の凍結乾燥方法
CA2078601A1 (fr)	1993-03-21	Production de cristaux de peneme
JPS6024080B2 (ja)	1985-06-11	結晶の製造法
US2887487A (en)	1959-05-19	Production of anhydrous sterile preparations of alkali barbiturates and alkali thiobarbiturates
Clarke et al.	1974	Phase Diagrams for the Sodium and Potassium Benzoate–Water Systems
CN114306250A (zh)	2022-04-12	一种醋酸特利加压素制剂及其制备方法

Legal Events

Date	Code	Title	Description
1997-06-17	MKEX	Expiry